Connor Clark & Lunn Investment Management Ltd. Invests $2.23 Million in Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• Connor Clark & Lunn Investment Management purchased 153,008 Enanta Pharmaceuticals shares worth approximately $2.23 million, representing a 0.53% stake. Institutional investors collectively own 94.99% of the company.
• Enanta’s stock opened at $13.60, near its 50-day and 200-day moving averages, but the company reported a quarterly loss of $0.67 per share and revenue of $14.36 million, both below analyst expectations.
• Analyst sentiment remains mixed but leans positive: the stock has a consensus “Moderate Buy” rating and an average price target of $19.50, compared with its current price near $13.60.

Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 153,008 shares of the biotechnology company's stock, valued at approximately $2,231,000. Connor Clark & Lunn Investment Management Ltd. owned 0.53% of Enanta Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth $32,000. Seven Fleet Capital Management LP bought a new stake in Enanta Pharmaceuticals during the 4th quarter valued at $36,000. Strs Ohio purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at $50,000. Clearstead Trust LLC purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at $74,000. Finally, Quarry LP purchased a new position in shares of Enanta Pharmaceuticals in the third quarter valued at about $81,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Stock Down 1.4%

ENTA opened at $13.60 on Friday. The firm has a 50 day moving average price of $13.59 and a 200-day moving average price of $13.48. Enanta Pharmaceuticals, Inc. has a twelve month low of $7.05 and a twelve month high of $17.15. The stock has a market capitalization of $396.03 million, a price-to-earnings ratio of -5.64 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The firm had revenue of $14.36 million during the quarter, compared to the consensus estimate of $16.76 million. As a group, analysts expect that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Wall Street Zen cut shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $19.50.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source